معرفی
Dr. Li Shen is an Honorary Research Fellow at the University of Glasgow's School of Cardiovascular & Metabolic Health, specializing in cardiovascular research with a focus on heart failure mechanisms, clinical outcomes, and therapeutic interventions. His work integrates large clinical trial data (e.g., PARADIGM-HF, PARAGON-HF) to explore treatment efficacy across patient subgroups, including those with diabetes, renal impairment, and comorbidities like cancer.
Research interests include prognostic modeling for sudden/pump-failure death, drug safety (e.g., beta-blockers, sacubitril/valsartan), and disparities in heart failure outcomes based on race, gender, and socioeconomic factors. His studies often analyze biomarkers (e.g., prognostic nutritional index) and comorbidities (e.g., diabetes, frailty) to refine patient stratification and treatment strategies.
Recent articles highlight advancements in understanding heart failure subtypes (HFrEF/HFpEF), drug interactions in polypharmacy, and the impact of therapies like dapagliflozin in diabetic populations. Collaborations with global research networks (e.g., Swedish Heart Failure Registry) enhance the generalizability of findings.
Key contributions include validating predictive models for mortality/morbidity and investigating the declining incidence of sudden cardiac death in heart failure populations over time. This work informs precision medicine approaches and clinical guidelines for optimized heart failure management.